



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent licensee of the Blue Cross and Blue Shield Association

Medical Policy

Phrenic Nerve Stimulation for Central Sleep Apnea

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 955

BCBSA Reference Number: 2.02.33 (For Plan internal use only)

NCD/LCD: N/A

Related Policies

Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing Systems, #[593](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

The use of phrenic nerve stimulation for central sleep apnea is considered **INVESTIGATIONAL** in all situations.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is not a covered service.
Commercial PPO and Indemnity	This is not a covered service.
Medicare HMO Blue SM	This is not a covered service.
Medicare PPO Blue SM	This is not a covered service.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The following CPT and HCPCS codes are considered investigational for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

CPT Codes

CPT codes:	Code Description
33276	Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed
33277	Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)
33278	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)
33279	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only
33280	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only
33281	Repositioning of phrenic nerve stimulator transvenous lead(s)
33287	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator
33288	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)
93150	Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming
93151	Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system
93152	Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography
93153	Interrogation without programming of implanted phrenic nerve stimulator system

HCPCS Codes

HCPCS codes:	Code Description
C1823	Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads

Description

Central Sleep Apnea

Central sleep apnea (CSA) is characterized by repetitive cessation or decrease in both airflow and ventilatory effort during sleep. Central sleep apnea may be idiopathic or secondary (associated with a medical condition such as congestive heart failure, drugs, or high altitude breathing). Apneas associated with Cheyne-Stokes respiration are common among patients with heart failure (HF) or who have had strokes, and account for about half of the population with CSA. Central sleep apnea is less common than obstructive sleep apnea. Based on analyses of a large community-based cohort of participants 40 years of age and older in the Sleep Heart Health Study, the estimated prevalence of CSA and obstructive sleep apnea are 0.9% and 47.6%, respectively.¹ Risk factors for CSA include age (>65 years), male gender, history of HF, history of stroke, other medical conditions (acromegaly, renal failure, atrial fibrillation, low cervical tetraplegia, and primary mitochondrial diseases), and opioid use. Individuals with CSA have

difficulty maintaining sleep and therefore experience excessive daytime sleepiness, poor concentration, and morning headaches, and are at higher risk for accidents and injuries.

Treatment

The goal of treatment is to normalize sleep-related breathing patterns. Because most cases of CSA are secondary to an underlying condition, central nervous system pathology, or medication side effects, treatment of the underlying condition or removal of the medication may improve CSA. Treatment recommendations differ depending on the classification of CSA as either hyperventilation-related (most common, including primary CSA and those relating to HF or high altitude breathing) or hypoventilation-related (less common, relating to central nervous system diseases or use of nervous system suppressing drugs such as opioids).

For patients with hyperventilation-related CSA, continuous positive airway pressure (CPAP) is considered first-line therapy. Due to CPAP discomfort, patient compliance may become an issue. Supplemental oxygen during sleep may be considered for patients experiencing hypoxia during sleep or who cannot tolerate CPAP. Patients with CSA due to HF with an ejection fraction >45%, and who are not responding with CPAP and oxygen therapy, may consider bilevel positive airway pressure or adaptive servo-ventilation (ASV) as second-line therapy. Bilevel positive airway pressure devices have 2 pressure settings, 1 for inhalation and 1 for exhalation. Adaptive servo-ventilation uses both inspiratory and expiratory pressure, and titrates the pressure to maintain adequate air movement. However, a clinical trial reported increased cardiovascular mortality with ASV in patients with CSA due to HF and with an ejection fraction <45%,² and therefore, ASV is not recommended for this group.

For patients with hypoventilation-related CSA, first-line therapy is bilevel positive airway pressure.

Pharmacologic therapy with a respiratory stimulant may be recommended to patients with hyper- or hypoventilation CSA who do not benefit from positive airway pressure devices, though close monitoring is necessary due to the potential for adverse effects such as rapid heart rate, high blood pressure, and panic attacks.

Phrenic Nerve Stimulation

Several phrenic nerve stimulation systems are available for patients who are ventilator dependent. These systems stimulate the phrenic nerve in the chest, which sends signals to the diaphragm to restore a normal breathing pattern. Currently, there is 1 phrenic nerve stimulation device approved by the U.S. Food and Drug Administration (FDA) for CSA, the remedē System (Zoll Medical). A cardiologist implants the battery-powered device under the skin in the right or left pectoral region using local anesthesia. The device has 2 leads, 1 to stimulate a phrenic nerve (either the left pericardiophrenic or right brachiocephalic vein) and 1 to sense breathing. The device runs on an algorithm that activates automatically at night when the patient is in a sleeping position and suspends therapy when the patient sits up. Patient-specific changes in programming can be conducted externally by a programmer.

Summary

Central sleep apnea (CSA) is characterized by sleep-disordered breathing due to diminished or absent respiratory effort. Central sleep apnea may be idiopathic or secondary (associated with a medical condition, drugs, or high altitude breathing). The use of positive airway pressure devices is currently the most common form of therapy for CSA. An implantable device that stimulates the phrenic nerve in the chest is a potential alternative treatment. The battery-powered device sends signals to the diaphragm in order to stimulate breathing and normalize sleep-related breathing patterns.

For individuals with CSA who receive phrenic nerve stimulation, the evidence includes a systematic review, 1 randomized controlled trial (RCT), and observational studies. Relevant outcomes are change in disease status, functional outcomes, and quality of life. The RCT compared the use of phrenic nerve stimulation to no treatment among patients with CSA of various etiologies. All patients received implantation of the phrenic nerve stimulation system, with activation of the system after 1 month in the intervention group and activation after 6 months in the control group. Activation is delayed 1 month after implantation to allow for lead healing. At 6 months follow-up, the patients with the activated device

experienced significant improvements in several sleep metrics and quality of life measures. At 12 months follow-up, patients in the activated device arm showed sustained significant improvements from baseline in sleep metrics and quality of life. A subgroup analysis of patients with heart failure combined 6- and 12-month data from patients in the intervention group and 12- and 18-month data from the control group. Results from this subgroup analysis showed significant improvements in sleep metrics and quality of life at 12 months compared with baseline. Results from observational studies supported the results of the RCT. An invasive procedure would typically be considered only if non-surgical treatments had failed, but there is limited data in which phrenic nerve stimulation was evaluated in patients who had failed the current standard of care, positive airway pressure, or respiratory stimulant medication. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
7/2024	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2024	Clarified coding information.
7/2023	Annual policy review. References updated. Policy statements unchanged.
1/2023	PA information section clarified to include Medicare.
6/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
6/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference. Clarified coding information.
7/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
7/2019	Ongoing investigational statement on phrenic nerve stimulation for the treatment of central sleep apnea was transferred from policy #593.
11/2018	MPA literature review. Investigational policy statements clarified. Policy statements unchanged.
9/2017	MPA literature review. Policy statements unchanged.
8/2015	Coding information clarified.
9/2013	New policy describing investigational indications. Effective 9/1/2013.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Donovan LM, Kapur VK. Prevalence and Characteristics of Central Compared to Obstructive Sleep Apnea: Analyses from the Sleep Heart Health Study Cohort. *Sleep*. Jul 01 2016; 39(7): 1353-9. PMID 27166235
2. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. *N Engl J Med*. Sep 17 2015; 373(12): 1095-105. PMID 26323938
3. Wang Y, Huang Y, Xia M, et al. Effect of phrenic nerve stimulation on patients with central sleep apnea: A meta-analysis. *Sleep Med Rev*. Aug 2023; 70: 101819. PMID 37467524
4. Costanzo MR, Javaheri S, Ponikowski P, et al. Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. *Nat Sci Sleep*. 2021; 13: 515-526. PMID 33953626

5. Oldenburg O, Costanzo MR, Germany R, et al. Improving Nocturnal Hypoxemic Burden with Transvenous Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. *J Cardiovasc Transl Res.* Apr 2021; 14(2): 377-385. PMID 32789619
6. Costanzo MR, Goldberg LR, Ponikowski P, Augostini R, Stellbrink C, Abraham W. Phrenic nerve stimulation for central sleep apnea is effective and safe in the presence of concomitant cardiac devices. *J Card Fail.* Aug 2018; 24(8):S17-8.
7. Zhang X, Ding N, Ni B, et al. Safety and feasibility of chronic transvenous phrenic nerve stimulation for treatment of central sleep apnea in heart failure patients. *Clin Respir J.* Mar 2017; 11(2): 176-184. PMID 26072733
8. Fox H, Bitter T, Horstkotte D, et al. Long-Term Experience with First-Generation Implantable Neurostimulation Device in Central Sleep Apnea Treatment. *Pacing Clin Electrophysiol.* May 2017; 40(5): 498-503. PMID 28211952
9. Jagielski D, Ponikowski P, Augostini R, et al. Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remedē® System. *Eur J Heart Fail.* Nov 2016; 18(11): 1386-1393. PMID 27373452
10. Costanzo MR, Ponikowski P, Javaheri S, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. *Lancet.* Sep 03 2016; 388(10048): 974-82. PMID 27598679
11. Abraham WT, Jagielski D, Oldenburg O, et al. Phrenic nerve stimulation for the treatment of central sleep apnea. *JACC Heart Fail.* May 2015; 3(5): 360-369. PMID 25770408
12. Ponikowski P, Javaheri S, Michalkiewicz D, et al. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. *Eur Heart J.* Apr 2012; 33(7): 889-94. PMID 21856678
13. Zhang XL, Ding N, Wang H, et al. Transvenous phrenic nerve stimulation in patients with Cheyne-Stokes respiration and congestive heart failure: a safety and proof-of-concept study. *Chest.* Oct 2012; 142(4): 927-934. PMID 22302299
14. Costanzo MR, Augostini R, Goldberg LR, et al. Design of the remedē System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. *J Card Fail.* Nov 2015; 21(11): 892-902. PMID 26432647
15. Costanzo MR, Ponikowski P, Javaheri S, et al. Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. *Am J Cardiol.* Jun 01 2018; 121(11): 1400-1408. PMID 29735217
16. Fox H, Oldenburg O, Javaheri S, et al. Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. *Sleep.* Oct 21 2019; 42(11). PMID 31634407
17. Baumert M, Immanuel S, McKane S, et al. Transvenous phrenic nerve stimulation for the treatment of central sleep apnea reduces episodic hypoxemic burden. *Int J Cardiol.* May 01 2023; 378: 89-95. PMID 36841294
18. Baumert M, Linz D, McKane S, et al. Transvenous phrenic nerve stimulation is associated with normalization of nocturnal heart rate perturbations in patients with central sleep apnea. *Sleep.* Sep 08 2023; 46(9). PMID 37284759
19. Hartmann S, Immanuel S, McKane S, et al. Transvenous phrenic nerve stimulation for treating central sleep apnea may regulate sleep microstructure. *Sleep Med.* Jan 2024; 113: 70-75. PMID 37988861
20. Samii S, McKane S, Meyer TE, et al. Analysis by sex of safety and effectiveness of transvenous phrenic nerve stimulation. *Sleep Breath.* Mar 2024; 28(1): 165-171. PMID 37436669
21. Costanzo MR, Ponikowski P, Coats A, et al. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. *Eur J Heart Fail.* Dec 2018; 20(12): 1746-1754. PMID 30303611
22. Hill L, Meyer T, McKane S, et al. Transvenous phrenic nerve stimulation to treat central sleep apnoea in patients with heart failure may improve sleep, quality of life, and symptoms. *Eur J Cardiovasc Nurs.* Jul 19 2023; 22(5): 489-497. PMID 36125322
23. Wang Y, Schoebel J, Han J, et al. Phrenic nerve stimulation for the treatment of central sleep apnea in patients with heart failure. *Sleep Breath.* Jun 2023; 27(3): 1027-1032. PMID 35978055
24. Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep.* Jan 01 2012; 35(1): 17-40. PMID 22215916
25. Aurora RN, Bista SR, Casey KR, et al. Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses". *J Clin Sleep Med.* May 15 2016; 12(5): 757-61. PMID 27092695

26. Centers for Medicare and Medicaid Services. Local Coverage Determination: Transvenous Phrenic Nerve Stimulation in the Treatment of Central Sleep Apnea (A57548) 2019
https://localcoverage.cms.gov/mcd_archive/view/article.aspx?articleInfo=57548:10. Last Accessed April 11, 2024.